| Literature DB >> 33355178 |
Antoni Ribas1, Rajarshi Sengupta2, Trevan Locke2, Sayyed Kaleem Zaidi2, Katie M Campbell3, John M Carethers4, Elizabeth M Jaffee5, E John Wherry6, Jean-Charles Soria7, Gypsyamber D'Souza.
Abstract
Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination. ©2020 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33355178 PMCID: PMC8053003 DOI: 10.1158/2159-8290.CD-20-1817
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 38.272